Chronic ulcers represent a major public health concern and constitute a common cause of morbidity and mortality. These wounds, associated with delayed and disorderly healing, are difficult to treat and comprise a significant unmet medical need. Chronic ulcers represent a major public health concern and constitute a common cause of morbidity and mortality. These wounds, associated with delayed and disorderly healing, are difficult to treat and comprise a significant unmet medical need.

Tobacco plants were genetically engineered to produce human type I collagen. The device is not available for sale in the EU or US and does not have regulatory approval.

**Background**

**Goal**

To test the performance of wound healing scaffolds made of human recombinant type I collagen (rhCollagen) for the treatment of acute, chronic, and tunneled wounds.

**Human Recombinant Collagen Type I (rhCollagen) Technology**

Tobacco plants were genetically engineered to produce functional human type I collagen.

**Product Description**

- **rhCollagen syringe**
  - Empty syringe for saline administration, luer lock connector and flexible cannula
  - Biocompatible
  - Stored at Room Temperature
  - Single use kit
  - Sterile

**Product Indications**

rhCollagen Flowable Gel is indicated for use in partial and full-thickness tunneled wounds such as diabetic ulcers, pressure ulcers, venous ulcers, chronic vascular ulcers, surgical and traumatic wounds.

**Product Advantages**

- Homogenous human collagen
- Free of risks of hypersensitivity and diseases, inherent to animal and cadaver derived collagen
- Safe and Biocompatible for human use

**Conclusions**

- Accelerates wound closure
- Promotes epithelialization
- Minimizes foreign body response
- Induces early angiogenesis and remodeling